CX3CR1 and cancer: Hence, the release of CX3CL1 by the MTX-induced dying cancer cells (Figures 1C, F) may establish a gradient directed towards the tumour, presumably augmenting CX3CR1+ immune cell migration along the gradient and activation of an anti-tumour immune cycle.